**Feedback on Proposed Improvements to the Drug Reimbursement Review Process**

# Purpose of Consultation

Canada’s Drug Agency (CDA-AMC) is inviting interested parties to provide their views and feedback on our proposed improvements and new approaches to the drug Reimbursement Review process.

How to Participate in the Consultation

To provide comments on the proposal, please use this template and send to [feedback@cda-amc.ca](mailto:feedback@cda-amc.ca). Feedback must be received by **5:00 p.m. ET on February 6, 2025**. For feedback to be considered, individuals and organizations must be identified by name in the template. One response per organization will be considered. Questions about the feedback process can be sent to [feedback@cda-amc.ca](mailto:feedback@cda-amc.ca).

Planned Implementation Dates

We are targeting the following implementation timeline for these revisions.

* Consultation opens: January 6, 2025
* Consultation closes: February 6, 2025
* Revised procedures posted: February 27, 2025
* Effective for new applications targeting the October 2025 expert committee meetings: Oncology applications received on or after April 28, 2025, and non-oncology applications received on or after May 12, 2025

Next Steps

Following the consultation period, CDA-AMC will carefully assess all feedback before announcing the final details of the new drug Reimbursement Review process. This may involve disclosing some or all comments, materials, and summaries to our advisory bodies and the participating jurisdictions. We thank individuals and organizations in advance for their interest in our drug Reimbursement Review process.

**Feedback on Proposed Improvements to the Drug Reimbursement Review Process**

|  |  |
| --- | --- |
| **Organization providing feedback:** | Insert organization name |
| **Contact person:** | Insert contact person |
| **Title:** | Insert title |
| **Email address:** | Insert email address |

If your organization is not submitting feedback on this section, please indicate: No relevant feedback to submit.

| **Section of consultation** | **Feedback** |
| --- | --- |
| 1. **Proportionate review processes** | |
| * 1. Revised procedures for tailored reviews | Insert feedback. |
| * 1. Revised procedures for complex reviews | Insert feedback. |
| * 1. Simplifying the resubmission processes | Insert feedback. |
| 1. **Review and recommendation reporting** | |
| * 1. Review report templates | Insert feedback. |
| * 1. Recommendation report template | Insert feedback. |
| * 1. Process for redacting review reports | Insert feedback. |
| 1. **Deliberative process** | |
| * 1. Presentation by a person with lived experience | Insert feedback. |
| * 1. Deliberative framework | Insert feedback. |
| * 1. Drafting recommendations | Insert feedback. |
| 1. **Accelerated access pathways** | |
| * 1. Rolling submissions | Insert feedback. |
| * 1. Proposed minor expansion of time-limited recommendations to resubmissions | Insert feedback. |
| 1. **Checkpoints with sponsors throughout the drug Reimbursement Review process** | |
| * 1. New presubmission meeting format and purpose | Insert feedback. |
| * 1. New evidence presentation meeting | Insert feedback. |
| * 1. New in-review meeting | Insert feedback. |
| * 1. Reconsideration meeting | Insert feedback. |
| * 1. New postsubmission meetings | Insert feedback. |
| 1. **Application requirements for sponsor submissions** | |
| * 1. Streamlining application requirements | Insert feedback. |
| * 1. Indirect treatment comparisons and individual patient data–based comparisons | Insert feedback. |
| * 1. Proposed reimbursement conditions | Insert feedback. |
| * 1. Clinical expert suggestions | Insert feedback. |
| * 1. Citing Clinical Study Report data in the sponsor summary of clinical evidence | Insert feedback. |
| * 1. Declining to file a Reimbursement Review submission | Insert feedback. |
| * 1. New consolidated eligibility inquiry form | Insert feedback. |